Novo Nordisk will provide Variant with an upfront payment and additional near-term R&D funding that could reach up to $50m.

Variant Bio is partnering with Novo Nordisk to study metabolic diseases including obesity, using Variant's genomic data from diverse populations.

On Tuesday, his company, Variant Bio, based in Seattle, announced a $50 million collaboration with the drugmaker Novo Nordisk to develop drugs for metabolic disorders, including diabetes and ...

On Friday, however, Novo Nordisk announced top-line results in yet another trial. While the results don't initially sound as ...

Looking to expand its legacy in metabolic conditions, Novo Nordisk has inked a multiyear research pact with Variant Bio to better understand the genetics underlying disease across diverse populations.

Novo Nordisk shares were 9.5% higher after the pharmaceutical giant said an experimental weight-loss shot showed patients ...

Novo Nordisk's U.S.-listed shares are surging 9% Friday morning after the Danish drugmaker reported early stage results for ...

Novo Nordisk shares jump close to 14% on promising trial results for amycretin, a once-weekly obesity drug, signaling fierce ...

Commercial terms include an upfront payment and additional near-term R&D funding totaling up to $50 million, plus potential option and milestone payments SEATTLE, Jan. 7, 2025 /PRNewswire ...

Here are some of the major companies whose stocks moved on the week’s news.

Variant Bio has entered a multi-year research partnership with Novo Nordisk, focusing on the identification of new targets to treat metabolic conditions. Leveraging Variant’s ‘VB-Inference ...